346.50 USD
-0.17
0.05%
At close Apr 17, 4:00 PM EDT
After hours
346.50
+0.00
0.00%
1 day
-0.05%
5 days
-1.32%
1 month
-7.23%
3 months
-9.63%
6 months
-3.68%
Year to date
-3.41%
1 year
3.12%
5 years
82.84%
10 years
274.59%
 

About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one fourth of Stryker's total revenue currently comes from outside the United States.

Employees: 53,000

0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 10 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

194% more first-time investments, than exits

New positions opened: 259 | Existing positions closed: 88

17% more repeat investments, than reductions

Existing positions increased: 826 | Existing positions reduced: 703

7% more funds holding

Funds holding: 1,999 [Q3] → 2,130 (+131) [Q4]

2% more capital invested

Capital invested by funds: $106B [Q3] → $108B (+$1.8B) [Q4]

0.66% more ownership

Funds ownership: 77.13% [Q3] → 77.8% (+0.66%) [Q4]

6% less call options, than puts

Call options by funds: $518M | Put options by funds: $550M

4% less funds holding in top 10

Funds holding in top 10: 76 [Q3] → 73 (-3) [Q4]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$413
19%
upside
Avg. target
$437
26%
upside
High target
$450
30%
upside

10 analyst ratings

positive
80%
neutral
20%
negative
0%
Needham
Mike Matson
23% 1-year accuracy
28 / 121 met price target
28%upside
$442
Buy
Reiterated
21 Mar 2025
Citigroup
Joanne Wuensch
42% 1-year accuracy
18 / 43 met price target
30%upside
$450
Buy
Reinstated
26 Feb 2025
Barclays
Matt Miksic
44% 1-year accuracy
18 / 41 met price target
28%upside
$443
Overweight
Maintained
10 Feb 2025
Goldman Sachs
David Roman
25% 1-year accuracy
5 / 20 met price target
23%upside
$427
Neutral
Maintained
30 Jan 2025
Truist Securities
Richard Newitter
54% 1-year accuracy
26 / 48 met price target
19%upside
$413
Hold
Maintained
30 Jan 2025

Financial journalist opinion

Based on 7 articles about SYK published over the past 30 days

Neutral
Zacks Investment Research
4 days ago
The Zacks Analyst Blog Bank of America, Chevron, Stryker, Value Line and Sypris
Bank of America, Chevron, Stryker, Value Line and Sypris are included in this Analyst Blog.
The Zacks Analyst Blog Bank of America, Chevron, Stryker, Value Line and Sypris
Positive
Zacks Investment Research
1 week ago
PBH vs. SYK: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical - Products sector have probably already heard of Prestige Consumer Healthcare (PBH) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?
PBH vs. SYK: Which Stock Is the Better Value Option?
Neutral
GlobeNewsWire
2 weeks ago
Viscogliosi Brothers Completes Acquisition of U.S. Spine Business from Stryker, Creating VB Spine, LLC
VB Spine is a Strategic Partner to Stryker with Access to Mako Spine and Copilot Marc, John and Anthony Viscogliosi Lead VB Spine as Co-Chief Executive Officers NEW YORK, April 01, 2025 (GLOBE NEWSWIRE) -- Viscogliosi Brothers, LLC, a family-owned investment office specializing in the neuro-musculoskeletal space, today announced the successful completion of its previously announced acquisition of the U.S. spine business from Stryker (NYSE: SYK). The business will operate as a standalone company under the name VB Spine, LLC (“VB Spine”).
Viscogliosi Brothers Completes Acquisition of U.S. Spine Business from Stryker, Creating VB Spine, LLC
Neutral
GlobeNewsWire
2 weeks ago
Stryker completes sale of U.S. spinal implants business
Portage, Michigan, April 01, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the sale of its U.S. spinal implants business to Viscogliosi Brothers, LLC, as part of the newly formed company VB Spine, LLC.
Stryker completes sale of U.S. spinal implants business
Negative
Investors Business Daily
3 weeks ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Neutral
GlobeNewsWire
3 weeks ago
Stryker announces intention to nominate Manny Maceda to board of directors
Portage, Michigan, March 26, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced that its board of directors has nominated Emmanuel “Manny” Maceda for election to the company's board at the 2025 Annual Meeting of Shareholders, scheduled for May 8, 2025.
Stryker announces intention to nominate Manny Maceda to board of directors
Neutral
GlobeNewsWire
3 weeks ago
Stryker announces Annual Meeting of Shareholders
Portage, Michigan, March 25, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced its 2025 Annual Meeting of Shareholders is scheduled as follows:
Stryker announces Annual Meeting of Shareholders
Positive
Zacks Investment Research
1 month ago
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan
Tariffs are shaking up the Medical Device industry, but SYK, MDT & PODD are poised to thrive. Here's why three key players remain strong despite rising trade tensions.
3 Tariff-Proof Medical Device Stocks to Watch Amid Trump's MAGA Slogan
Positive
Schwab Network
1 month ago
The Big 3: MMM, PM, SYK
Today's Big 3 focuses on what Dan Deming calls "defensive" plays in a market still exhibiting elevated volatility. He talks about why there's upside potential in 3M (MMM), Philip Morris (PM) and Stryker (SYK).
The Big 3: MMM, PM, SYK
Neutral
Zacks Investment Research
1 month ago
Stryker Unveils Next-Generation Mako SmartRobotics but Stock Falls
SYK unveils next-gen Mako SmartRobotics, revolutionizing hip, knee and spine surgeries with greater precision and first-to-market robotic hip revision technology.
Stryker Unveils Next-Generation Mako SmartRobotics but Stock Falls
Charts implemented using Lightweight Charts™